(thirdQuint)Study Comparing SUBA-Itraconazole With SPORANOX (Itraconazole) in the Treatment of Onychomycosis.

 Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel designed study comparing a dosing regimen of 100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA cent -Itraconazole 50 mg capsules (HalcyGen Ltd) to the approved dosing regimen of 200 mg taken with breakfast of SPORANOX(R) (itraconazole) 100 mg capsules (Janssen Pharma).

 Patients will be randomly assigned in a 3:3:1 ratio to the test product 100 mg once-a-day: reference product 200 mg once-a-day: placebo once-a-day.

 respectively.

 The patients will complete 5 visits: baseline/screening (within 28 days of randomization), Day 1 (randomization), Week 6, Week 12 and Week 24.

.

 Study Comparing SUBA-Itraconazole With SPORANOX (Itraconazole) in the Treatment of Onychomycosis@highlight

The objective of this study is to compare the relative efficacy and safety of SUBA cent -Itraconazole Capsules (HalcyGen Ltd) to an already marketed oral formulation of itraconazole SPORANOX(R) (itraconazole) capsules (Janssen Pharma) in the treatment of onychomycosis of the toenail.

 Both the test and the reference formulations will also be compared to a placebo formulation to test for superiority.

